Download

Full Text

• Bruner, K.M., Murray, A.J., Pollack, R.A., et al. Defective proviruses rapidly accumulate during acute HIV-1 infection. Nat Med, 22, 2016, 10.1038/nm.4156.
• Perelson, A.S., Neumann, A.U., Markowitz, M., Leonard, J.M., Ho, D.D., HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271 (1996), 1582–1586 (80-).
• Wei, X., Ghosh, S.K., Taylor, M.E., et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373 (1995), 117–122.
• Chavez, L., Calvanese, V., Verdin, E., HIV latency is established directly and early in both resting and activated primary CD4 T cells. PLoS Pathog 11 (2015), 1–21.
• van der Sluis, R.M., van Montfort, T., Pollakis, G., et al. Dendritic cell-induced activation of Latent HIV-1 provirus in actively proliferating primary T lymphocytes. PLoS Pathog, 9, 2013, e1003259.
• Darcis, G., Van Driessche, B., Bouchat, S., Kirchhoff, F., Van Lint, C., Molecular control of HIV and SIV latency. Current topics in Microbiology and Immunology, 2017, Springer Berlin Heidelberg, Berlin, Heidelberg, 1–22.
• Yukl, S.A., Kaiser, P., Kim, P., et al. HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing. Sci Transl Med, 10, 2018 http://stm.sciencemag.org/content/10/430/eaap9927.abstract.
• Huang, J., Wang, F., Argyris, E., et al. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+T lymphocytes. Nat Med 13 (2007), 1241–1247.
• Zolotukhin, A.S., Michalowski, D., Bear, J., et al. PSF acts through the human immunodeficiency virus type 1 mRNA instability elements to regulate virus expression. Mol Cell Biol 23 (2003), 6618–6630.
• Kula, A., Gharu, L., Marcello, A., HIV-1 pre-mRNA commitment to Rev mediated export through PSF and Matrin 3. Virology 435 (2013), 329–340.
• Yedavalli, V.S.R.K., Jeang, K.T., Matrin 3 is a co-factor for HIV-1 Rev in regulating post-transcriptional viral gene expression. Retrovirology 8 (2011), 1–10.
• Ho, Y.-C., Laird, G.M., Siliciano, R.F., Measuring reversal of HIV-1 latency ex vivo using cells from infected individuals. Proc Natl Acad Sci 111 (2014), 6860–6861.
• Hosmane, N.N., Kwon, K.J., Bruner, K.M., et al. Proliferation of latently infected CD4+ T cells carrying replication-competent HIV-1: potential role in latent reservoir dynamics. J Exp Med 214 (2017), 959–972.
• van Montfort, T., Thomas, A.A.M., Pollakis, G., Paxton, W.A., Dendritic cells preferentially transfer CXCR4-using human immunodeficiency virus type 1 variants to CD4+ T lymphocytes in trans. J Virol 82 (2008), 7886–7896.
• Del Prete, G.Q., Haggarty, B., Leslie, G.J., et al. Derivation and characterization of a simian immunodeficiency virus SIVmac239 variant with tropism for CXCR4. J Virol 83 (2009), 9911–9922.
• van der Sluis, R.M., van Capel, T.M.M., Speijer, D., et al. Dendritic cell type-specific HIV-1 activation in effector T cells. AIDS 29 (2015), 1003–1014.
• Boom, R., Sol, C., Salimans, M., Jansen, C., Wertheim-van Dillen, P., van der Noordaa, J., Rapid and simple method for purification of nucleic acids. J Clin Microbiol 28 (1990), 495–503.
• Malnati, M.S., Scarlatti, G., Gatto, F., et al. A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load. Nat Protoc, 3, 2008, 1240.
• Fun, A., Mok, H.P., Wills, M.R., Lever, A.M., A highly reproducible quantitative viral outgrowth assay for the measurement of the replication-competent latent HIV-1 reservoir. Sci Rep 7 (2017), 1–10.
• Rocha-Perugini, V., Sánchez-Madrid, F., Del Hoyo, G.M., Function and dynamics of tetraspanins during antigen recognition and immunological synapse formation. Front Immunol 6 (2016), 1–12.
• Rocha-Perugini, V., González-Granado, J.M., Tejera, E., López-Martín, S., Yañez-Mó, M., Sánchez-Madrid, F., Tetraspanins CD9 and CD151 at the immune synapse support T-cell integrin signaling. Eur J Immunol 44 (2014), 1967–1975.
• Hemler, M.E., Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol 6 (2005), 801–811.
• Besnard, E., Hakre, S., Kampmann, M., et al. The mTOR complex controls HIV latency. Cell Host Microbe 20 (2016), 785–797.
• Shin, H.M., Kim, M.H., Kim, B.H., et al. Inhibitory action of novel aromatic diamine compound on lipopolysaccharide-induced nuclear translocation of NF-κB without affecting IκB degradation. FEBS Lett 571 (2004), 50–54.
• van Montfort, T., Eggink, D., Boot, M., et al. HIV-1 N-glycan composition governs a balance between dendritic cell-mediated viral transmission and antigen presentation. J Immunol 187 (2011), 4676–4685.
• van Montfort, T., Thomas, A.A.M., Krawczyk, P.M., Berkhout, B., Sanders, R.W., Paxton, W.A., Reactivation of neutralized HIV-1 by dendritic cells is dependent on the epitope bound by the antibody. J Immunol 195 (2015), 3759–3768.
• Zhang, L., Ramratnam, B., Tenner-Racz, K., et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 340 (1999), 1605–1613.
• Kieffer, T.L., Kwon, P., Nettles, R.E., Han, Y., Ray, S.C., Siliciano, R.F., G → A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4 + T cells in vivo G3A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 resid. J Virol 79 (2005), 1975–1980.
• Sanchez, G., Xu, X., Chermann, J.C., Hirsch, I., Accumulation of defective viral genomes in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected individuals. J Virol 71 (1997), 2233–2240.
• Bullen, C.K., Laird, G.M., Durand, C.M., Siliciano, J.D., Siliciano, R.F., New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 20 (2014), 425–429.
• Laird, G.M., Bullen, C.K., Rosenbloom, D.I.S., et al. Ex Vivo Analysis Identifies Effective HIV-1 Latency – Reversing Drug Combinations. 125, 2015, 1–12.
• Berditchevski, F., Tolias, K.F., Wong, K., Carpenter, C.L., Hemler, M.E., A novel link between integrins, transmembrane-4 superfamily proteins (CD63 and CD81), and phosphatidylinositol 4-kinase. J Biol Chem 6 (1997), 2595–2598.
• Mittelbrunn, M., Yáñez-Mó, M., Sancho, D., Ursa, A., Sánchez-Madrid, F., Cutting edge: dynamic redistribution of tetraspanin CD81 at the central zone of the immune synapse in both T lymphocytes and APC. J Immunol 169 (2002), 6691–6695.
• Lin, W., Fan, Z., Immunological synapse molecules. J Immuno Biol 1 (2016), 1–6.
• Pawson, T., Scott, J.D., Signaling through scaffold, anchoring, and adaptor proteins. Science 278 (1997), 2075–2080 (80-).
• Li, Y.Q., Hii, C.S.T., Der, C.J., Ferrante, A., Direct evidence that ERK regulates the production/secretion of interleukin-2 in PHA/PMA-stimulated T lymphocytes. Immunology 96 (1999), 524–528.
• Coudronniere, N., Villalba, M., Englund, N., Altman, A., NF-κB activation induced by T cell receptor/CD28 costimulation is mediated by protein kinase C-θ. Proc Natl Acad Sci 97 (2000), 3394–3399.
• Darcis, G., Kula, A., Bouchat, S., et al. An in-depth comparison of latency-reversing agent combinations in various in vitro and ex vivo HIV-1 latency models identified bryostatin-1+JQ1 and ingenol-B+JQ1 to potently reactivate viral gene expression. PLoS Pathog, 11, 2015, e1005063.
• Mendoza, M.C., Er, E.E., Blenis, J., The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 36 (2011), 320–328.
• Calne, R.Y., Lim, S., Samaan, A., et al. Rapamycin for Immunosuppression in Organ Allografting. Lancet, 334, 1989, 227.
• Ernst, E., Neumann, C.H., Laporte, J.R., Jarnet, J., Woo, J., Immunosuppressive properties of FK-506 and rapamycin. Lancet 2 (1989), 443–444.
• Martin, A.R., Pollack, R.A., Capoferri, A., Ambinder, R.F., Durand, C.M., Siliciano, R.F., Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity. J Clin Invest 127 (2017), 651–656.
• Ren, X.-X., Ma, L., Sun, W.-W., et al. Dendritic cells maturated by co-culturing with HIV-1 latently infected Jurkat T cells or stimulating with AIDS-associated pathogens secrete TNF-alpha to reactivate HIV-1 from latency. Virulence, 1(12), 2017.
• Donaghy, H., Pozniak, A., Gazzard, B., et al. Patients With HIV-1 Infection Correlates With HIV-1 RNA Virus Load Brief Report Loss of Blood CD11c ϩ Myeloid and CD11c Ϫ Plasmacytoid Dendritic Cells in Patients With HIV-1 Infection Correlates With HIV-1 RNA Virus Load. 98, 2012, 2574–2576.
• Lorenzo-Redondo, R., Fryer, H.R., Bedford, T., et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature 530 (2016), 51–56.
• Pasternak, A.O., De Bruin, M., Jurriaans, S., et al. Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma. J Infect Dis 206 (2012), 1443–1452.
• Gramatica, A., Greene, W.C., Montano, M., Lymphoid tissue and blood CD4 T cells respond differently to latency-reversing agents: are we testing the right cells?. J Virus Erad, 2015, 2015.
• Archin, N.M., Liberty, A.L., Kashuba, A.D., et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487 (2012), 482–485.
• Søgaard, O.S., Graversen, M.E., Leth, S., et al. The depsipeptide romidepsin reverses HIV-1 latency in vivo. PLoS Pathog 11 (2015), 1–22.
• Rasmussen, T.A., Tolstrup, M., Brinkmann, C.R., et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 1 (2018), e13–e21.
• Gutiérrez, C., Serrano-Villar, S., Madrid-Elena, N., et al. Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy. AIDS 30 (2016), 1385–1392.
• Spivak, A.M., Andrade, A., Eisele, E., et al. A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis 58 (2014), 883–890.
• Palucka, K., Banchereau, J., Dendritic-cell-based therapeutic cancer vaccines. Immunity 39 (2013), 38–48.
• Prins, J.M., Jurriaans, S., van Praag, R.M., et al. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 13 (1999), 2405–2410.
• Sanyal, A., Mailliard, R.B., Rinaldo, C.R., et al. Novel assay reveals a large, inducible, replication-competent HIV-1 reservoir in resting CD4+T cells. Nat Med 23 (2017), 885–889.
• Bunney, T.D., Katan, M., Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer 10 (2010), 342–352.
• Downward, J., Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3 (2003), 11–22.